Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Keymed’s Claudin 18.2 ADC Granted China Breakthrough Status for Gastric Cancer

publication date: Sep 22, 2022

Chengdu Keymed Biosciences announced that its Claudin 18.2-targeted ADC was granted Breakthrough Therapy Designation to treat advanced gastric and gastroesophageal junction cancer in China. CMG901 is aimed at Claudin 18.2-expressing solid tumors. Earlier this year, CMG901 was awarded Fast Track Designation in the US for a similar indication following Keymed’s Phase I trial of the candidate, which assessed the safety, tolerability, pharmacokinetics and preliminary efficacy of CMG901. Keymed currently has nine clinical-stage projects including three bi-specific candidates and one antibody. More details....

Stock Symbol: (HK:02162)

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital